



Standing Way Eaglestone Milton Keynes MK6 5LD 01908 660033 www.mkuh.nhs.uk

## Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Tuesday 16<sup>th</sup> April 2024. I am pleased to confirm the following.

1.Do you treat patients with acute myeloid leukaemia (AML) in your Trust?

Yes

2. Where do patients diagnosed with AML in your Trust receive treatment?

**Cancer Centre** 

Azacitidine monotherapy

3.Please complete the table below with how many <u>newly diagnosed</u> patients with AML have <u>started first-line treatment</u> with each of the following therapies during the 6-month period October 2023 to March 2024?

Low dose cytarabine (LoDAC) monotherapy

Venetoclax + azacitidine

Venetoclax + LoDAC

Ivosidenib

Intensive chemotherapy-based regimen

Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)

Best supportive care
Other

Do <u>not</u> include prophylactic therapies such as GCSF, anti-fungals, antihistamines, antinauseants.

Note: this should only include patients with AML who have <u>started first-line treatment during</u> the 6-month window

Answer:





**Chief Executive: Joe Harrison** 

**Chair: Alison Davis** 

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period October 2023 to March 2024
Azacitidine monotherapy	0
(LoDAC) monotherapy	0
Venetoclax + azacitidine	4
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	8
Best supportive care	information not available on cancer ePMA
Other	none

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.